Cover Image
市場調查報告書

靜脈注射免疫球蛋白的全球市場 - 規模,佔有率,全球的趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔與預測 (2014∼2021年)

Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021

出版商 Allied Market Research 商品編碼 329498
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
靜脈注射免疫球蛋白的全球市場 - 規模,佔有率,全球的趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔與預測 (2014∼2021年) Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021
出版日期: 2015年04月15日 內容資訊: 英文 145 Pages
簡介

現在,免疫球蛋白產業在FDA/EMA的認證擴大和政府的支援下持續擴大。但治療費用高、副作用、政府嚴格法規及核可期長都是阻礙市場成長的要素。一般認為雖然有免疫球蛋白的供給等問題,但全球IVIG市場今後也將顯著成長。

本報告提供全球靜脈注射免疫球蛋白市場相關調查,提供您市場現狀及2021年為止的預測,各地區的競爭趨勢,市場機會等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 靜脈注射免疫球蛋白概要
  • 慢性疾病的流行與病學經濟負擔
  • IVIG治療的副作用成本
  • 調查結果
  • 波特五力分析
  • 價值鏈分析
  • 市場佔有率分析 (2014年)
  • IVIG市場上產品方案
  • 政府的法規與給付
  • IVIG的適應
  • 靜脈注射免疫球蛋白的成分分析
  • 臨床實驗
  • IVIG市場專利分析 (2011∼2014年)
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 各用途全球IVIG市場:2014∼2021年

  • 低伽馬球蛋白血症
  • 缺乏免疫力
  • 先天的AIDS
  • 慢性淋巴球性白血病
  • 重症肌無力
  • 多巢性運動神經病
  • 免疫性血小板減少性疾病
  • 川崎病
  • Guillain-Barre症候群
  • 其他

第5章 各產品全球IVIG市場:2014∼2021年

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

第6章 各地區全球IVIG市場:2014∼2021年

  • 市場規模與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第7章 企業簡介

  • Biotest AG
  • Octapharma AG
  • Baxter International Inc.
  • LFB Biotechnologies
  • China Biologics Products Inc.
  • Grifols S.A.
  • Kedrion Biopharma
  • CSL Behring
  • BDI Pharma Inc.
  • Bayer Healthcare

圖表

目錄
Product Code: PH 15325

IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases. In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period.

Global IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asia-pacific region, growing awareness for immunodeficiency disease & neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.

KEY BENEFITS

  • A comprehensive analysis of factors that drive and restrict the growth of the Global IVIG market. For instance, a large patient population and favorable government regulations will drive the Global IVIG market; however, the high cost of IVIG treatment and the associated risk of infection is likely to be a major restraint for the market.
  • The projections in the report are made by analyzing the current market trends and market potential for the period of 2014-2021, in terms of volume and value
  • The report covers a comprehensive analysis of all the geographic regions that help in determining the prevailing opportunities in these geographies. Government regulations regarding IVIG production and purification are discussed in detail
  • Competitive intelligence (of leading manufacturers of IVIG) helps in understanding the market scenario across geographies
  • SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies
  • The report provides a quantitative analysis of the current market and estimations through 2014-2021 that help in identifying the prevailing market opportunities.

KEY MARKET SEGMENT:

  • Global IVIG market is segmented based on the application, types and geography

MARKET BY APPLICATION

  • Hypogammaglobulinemia
  • Chronic Inflammatory demyelinating polyneuropathy (CIDP)
  • Immunodeficiency diseases
  • Congenital AIDS
  • Chronic Lymphocytic Leukaemia (CLL)
  • Myasthenia Gravis
  • Multifocal motor neuropathy
  • Idiopathic thrombocytopenic purpura (ITP)
  • Kawasaki disease
  • Guillain-Barre syndrome
  • Others

MARKET BY TYPE

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

MARKET BY GEOGRAPHY

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Russia
  • Austria
  • Italy
  • Others
  • Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • Others
  • LAMEA
  • Latin America
  • Middle East
  • Africa

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segment
  • 1.4. Research methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond what to expect by 2026($Million)
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Overview of Intravenous Immunoglobulin (IVIG)
    • 3.2.1. Patented products
  • 3.3. Epidemiology and economic burden of chronic conditions
  • 3.4. Cost of side effects due to IVIG treatments
  • 3.5. Key findings
    • 3.5.1. Top Factors Impacting global intravenous immunoglobulin market
    • 3.5.2. Top Investment pockets - Global Intravenous Immunoglobulin Market
  • 3.6. Porter's five forces analysis
    • 3.6.1. Bargaining power of buyers (Low)
    • 3.6.2. Bargaining power of suppliers (Low)
    • 3.6.3. Threat of new entrants (low)
    • 3.6.4. Threat of substitutes (low)
    • 3.6.5. Intense competitive rivalry (moderate)
  • 3.7. Value chain analysis
    • 3.7.1. Primary activities
    • 3.7.2. Support Activities
  • 3.8. Market share analysis (2014)
  • 3.9. Product scenario in IVIG market
  • 3.10. Government regulations and reimbursements
    • 3.10.1. Intravenous Immunoglobulin (IVIG) regulations in United States and Europe
    • 3.10.2. Reimbursements Scenario
  • 3.11. Indications for IVIG
    • 3.11.1. USFDA Indications
    • 3.11.2. European Medicine Agency
  • 3.12. Component analysis of intravenous immunoglobulins (IgG)
    • 3.12.1. IgG1
    • 3.12.2. IgG2
    • 3.12.3. IgG3
    • 3.12.4. IgG4
  • 3.13. Clinical trials
  • 3.14. Patent analysis of IVIG market (2011-2014)
    • 3.14.1. Patent analysis by geography
    • 3.14.2. U.S. patent analysis
    • 3.14.3. Europe Patent Analysis
  • 3.15. Market dynamics
    • 3.15.1. Drivers
      • 3.15.1.1. Rising Number of immunodeficieny Deficiency
      • 3.15.1.2. Increase in adoption ofIVIG
      • 3.15.1.3. Increasing Number of People with Bleeding Disorders
      • 3.15.1.4. Rising Ageing Population
    • 3.15.2. Restraints
      • 3.15.2.1. Stringent Regulations
      • 3.15.2.2. High Cost of Therapy
    • 3.15.3. Opportunities
      • 3.15.3.1. Opportunities in emerging economies
      • 3.15.3.2. Development of cost effective therapeutics through large scale production

CHAPTER 4 - GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021

  • 4.1. Hypogammaglobulinemia
  • 4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • 4.1. Immunodeficiency diseases
  • 4.2. Congenital AIDS
  • 4.3. Chronic Lymphocytic Leukemia
  • 4.4. Myasthenia Gravis
  • 4.5. Multifocal motor neuropathy
  • 4.6. Primary Immune thrombocytopenia (ITP)
  • 4.7. Kawasaki disease
  • 4.8. Guillain-Barre syndrome
  • 4.9. Others

CHAPTER 5 - GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET BY PRODUCT TYPES

  • 5.1. IgG
    • 5.1.1. Key Market Trends
    • 5.1.2. Clinical Interpretations
  • 5.2. IgA
    • 5.2.1. Key Market Trends
    • 5.2.2. Clinical interpretation
  • 5.3. IgM
    • 5.3.1. Key Market Trends
    • 5.3.2. Clinical Interpretation
  • 5.4. IgE
    • 5.4.1. Key Market Trends
    • 5.4.2. Clinical Interpretation
  • 5.5. IgD
    • 5.5.1. Key Market Trends

CHAPTER 6 - GLOBAL IVIG MARKET, BY GEOGRAPHY, 2014-2021

  • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. Key Market Trends
      • 6.2.1.2. Market size and forecast
    • 6.2.2. Canada
      • 6.2.2.1. Key Market Trends
      • 6.2.2.2. Market size and forecast
      • 6.2.2.3. Mexico
      • 6.2.2.4. Key Market Trends
      • 6.2.2.5. Market Size and forecast
  • 6.3. Europe
    • 6.3.1. Key market trends
    • 6.3.2. Market size and forecast
    • 6.3.3. U.K.
      • 6.3.3.1. Key Market Trend
      • 6.3.3.2. Market size and forecast
    • 6.3.4. France
      • 6.3.4.1. Key market trends
      • 6.3.4.2. Market size and forecast
    • 6.3.5. Germany
      • 6.3.5.1. Market size and forecast
    • 6.3.6. Italy
      • 6.3.6.1. Market size and forecast
    • 6.3.7. Austria
      • 6.3.7.1. market size and forecast
    • 6.3.8. Russia
      • 6.3.8.1. market size and forecast
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends
    • 6.4.2. Market size and forecast
    • 6.4.3. Australia
      • 6.4.3.1. Market size and forecast
    • 6.4.4. Japan
      • 6.4.4.1. Market size and forecast
    • 6.4.5. India
      • 6.4.5.1. Market size and forecast
    • 6.4.6. China
      • 6.4.6.1. Market size and forecast
    • 6.4.7. Others
      • 6.4.7.1. Market size and forecast
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends
    • 6.5.2. Market size and forecast
    • 6.5.3. Latin America
      • 6.5.3.1. Market size and forecast
    • 6.5.4. Middle East
      • 6.5.4.1. Market size and forecast
    • 6.5.5. Africa
      • 6.5.5.1. Market size and forecast

CHAPTER 7 - COMPANY PROFILES

  • 7.1. Biotest AG
    • 7.1.1. Company overview
    • 7.1.2. Biotest AG snapshot
    • 7.1.3. Operating business segment overview
    • 7.1.4. Financial performance
    • 7.1.5. Strategic moves and developments
    • 7.1.6. SWOT analysis of Biotest AG
  • 7.2. Octapharma AG
    • 7.2.1. Company overview
    • 7.2.2. Octapharma AG snapshot
    • 7.2.3. Operating business segment overview
    • 7.2.4. Strategic moves and developments
    • 7.2.5. SWOT analysis of Octapharma AG
  • 7.3. Baxter International Inc.
    • 7.3.1. Company overview
    • 7.3.2. Baxter International Inc. snapshot
    • 7.3.3. Operating business segments overview
    • 7.3.4. Financial performance
    • 7.3.5. Strategic moves and developments
    • 7.3.6. SWOT analysis of Baxter International Inc.
  • 7.4. LFB Biotechnologies
    • 7.4.1. Company overview
    • 7.4.2. LFB Biotechnologies snapshot
    • 7.4.3. Operating business segment overview
    • 7.4.4. Financial performance
    • 7.4.5. SWOT analysis of LFB biotechnologies
  • 7.5. China Biologics Products Inc.
    • 7.5.1. Company overview
    • 7.5.2. China Biologic Products Inc. Snapshot
    • 7.5.3. Operating business segment overview
    • 7.5.4. Financial performance
    • 7.5.5. Strategic moves and developments
    • 7.5.6. SWOT analysis of China Biologic Products Inc.
  • 7.6. Grifols S.A.
    • 7.6.1. Company overview
    • 7.6.2. Grifols S.A Snapshot
    • 7.6.3. Operating Business Segment Overview
    • 7.6.4. Financial performance
    • 7.6.5. Strategic moves and developments
    • 7.6.6. SWOT analysis Grifols S.A.
  • 7.7. Kedrion Biopharma
    • 7.7.1. Company overview
    • 7.7.2. Kedrion Biopharma. Snapshot
    • 7.7.3. Operating business segment overview
    • 7.7.4. Financial performance
    • 7.7.5. Strategic moves and developments
    • 7.7.6. SWOT Analysis of Kedrion Biopharma.
  • 7.8. CSL Behring
    • 7.8.1. Company overview
    • 7.8.2. CSL Behring Snapshot
    • 7.8.3. Operating business segment overview
    • 7.8.4. Financial performance
    • 7.8.5. Strategic moves and developments
    • 7.8.6. SWOT ANALYSIS of CSL Behring
  • 7.9. BDI Pharma Inc.
    • 7.9.1. Company overview
    • 7.9.2. BDI pharma Inc. Snapshot
    • 7.9.3. Operating business segment overview
    • 7.9.4. SWOT Analysis of BDI Pharma
  • 7.10. Bayer Healthcare
    • 7.10.1. Company overview
    • 7.10.2. Business performance
    • 7.10.3. Strategic moves and developments
    • 7.10.4. SWOT analysis of Bayer Healthcare

List of Tables

  • TABLE 1: MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, ($MILLION)
  • TABLE 2: MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
  • TABLE 3: RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, ($MILLION)
  • TABLE 4: RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
  • TABLE 5: DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, ($MILLION)
  • TABLE 6: DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
  • TABLE 7: IVIG PRODUCTS COMMERCIALIZED IN MARKET
  • TABLE 8: USFDA INDICATIONS FOR IVIG
  • TABLE 9: EMA APPROVED INDICATIONS FOR IVIG
  • TABLE 10: IGG SUBCLASS
  • TABLE 11: FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
  • TABLE 12: DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
  • TABLE 13: CLINICAL TRIALS FOR INTRAVENOUS IMMUNOGLOBULIN (2011-2014)
  • TABLE 14: PATENT ANALYSIS- UNITED STATES (2010-2014)
  • TABLE 15: PATENT ANALYSIS- EUROPE (2010-2014)
  • TABLE 16: WORLD AGING POPULATION 2013
  • TABLE 17: GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021, $MILLION
  • TABLE 18: GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021, (TONNE)
  • TABLE 19: COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
  • TABLE 20: HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 21: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 22: PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
  • TABLE 23: IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 24: IVIG PRODUCTS FOR CONGENITAL AIDS
  • TABLE 25: CONGENITAL AIDS IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 26: CLL STATISTICS 2011-2014
  • TABLE 27: CHRONIC LYMPHOCYTIC LEUKAEMIA IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 28: MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 29: MULTIFOCAL MOTOR NEUROPATHY IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 30: ITP TREATMENT OPTIONS
  • TABLE 31: ITP IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 32: KAWASAKI DISEASE PATIENTS PER 100,000 CHILDREN IN 2010
  • TABLE 33: KAWASAKI DISEASE IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 34: GUILLAIN-BARRE SYNDROME IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 35: OTHER IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
  • TABLE 36: GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, ($MILLION)
  • TABLE 37: GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (TONNE)
  • TABLE 38: NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
  • TABLE 39: NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
  • TABLE 40: EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
  • TABLE 41: EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
  • TABLE 42: HIGH PRIORITY INDICATIONS OF IVIG
  • TABLE 43: COST OF IVIG PRODUCTS IN UK
  • TABLE 44: PRODUCTS CONTAINING IVIG IN ITALIAN MARKET
  • TABLE 45: ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, ($MILLION)
  • TABLE 46: ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
  • TABLE 47: IMMUNOGLOBULIN BRANDS AND ITS MANUFACTURERS
  • TABLE 48: LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
  • TABLE 49: LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
  • TABLE 50: BIOTEST AG SANPSHOT
  • TABLE 51: OPERATING BUSINESS SEGMENT OVERVIEW
  • TABLE 52: OCTAPHARMA AG SNAPSHOT
  • TABLE 53: OCTAPHARMA AG OPERATING BUSNIESS OVERVIEW
  • TABLE 54: BAXTER INTERNATIONAL INC. SNAPSHOT
  • TABLE 55: OPERATING BUSINESS SEGMENTS OVERVIEW
  • TABLE 56: LFB BIOTECHNOLOGIES OPERATING SEGMENT OVERVIEW
  • TABLE 57: CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT
  • TABLE 58: CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW
  • TABLE 59: GRIFOLS S.A SNAPSHOT
  • TABLE 60: GRIFOLS S.A OPERATING SEGEMENTS
  • TABLE 61: KEDRION INC. SNAPSHOT
  • TABLE 62: KEDRION BIOPHARMA OPERATING SEGMENTS
  • TABLE 63: CSL BEHRING SNAPSHOT
  • TABLE 64: CSL BEHRING OPERATING SEGMENTS
  • TABLE 65: BDI PHARMA INC SNAPSHOT
  • TABLE 66: BDI PHARMA OPERATING SEGMENTS
  • TABLE 67: BAYER HEALTHCARE COMPANY SNAPSHOT

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN MODERATE GROWTH SCENARIO
  • FIG. 2: IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN RAPID GROWTH SCENARIO
  • FIG. 3: IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN DIMINISHING GROWTH SCENARIO
  • FIG. 4: PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
  • FIG. 5: TOP FACTORS IMPACTING GLOBAL IVIG MARKET (2015-2021)
  • FIG. 6: TOP INVESTMENT POCKETS - GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET
  • FIG. 7: PORTER'S FIVE FORCES ANALYSIS
  • FIG. 8: VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET
  • FIG. 9: MARKET SHARE ANALYSIS - GLOBAL IVIG MARKET 2014
  • FIG. 10: PATENT ANALYSIS BY GEOGRAPHY (2011-2014)
  • FIG. 11: U.S. PATENT ANALYSIS BY COMAPANY (2011-2014)
  • FIG. 12: EUROPE PATENT ANALYSIS, BY COMPANY (2011-2014)
  • FIG. 13: INCIDENCES OF HAEMOPHILIA, 2010
  • FIG. 14: BIOTEST AG FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)
  • FIG. 15: BIOTEST AG FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)
  • FIG. 16: SWOT ANALYSIS OF BIOTEST AG
  • FIG. 17: SWOT ANALYSIS OF OCTAPHARMA AG
  • FIG. 18: BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)
  • FIG. 19: BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)
  • FIG. 20: SWOT ANALYSIS OF BAXTER INTERNATIONAL INC
  • FIG. 21: L FB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY PRODUCT SEGMENT (2013)
  • FIG. 22: LFB BIOTECHNOLOGIES FINANTIAL PERFORMANCE BY GEOGRAPHY (2013)
  • FIG. 23: SWOT ANALYSIS OF LFB BIOTECHNOLOGIES
  • FIG. 24: CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE BY SEGMENTS
  • FIG. 25: SWOT ANALYSIS OF CHINA BIOLOGIC PRODUCTS INC.
  • FIG. 26: FINANCIAL OF GRIFOLS S.A BY GEOGRAPHY (2013)
  • FIG. 27: FINANCIAL GRIFOLS S.A. BY PRODUCT GROUPS (2013)
  • FIG. 28: SWOT ANALYSIS OF GRIFOLS S.A.
  • FIG. 29: FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2013)
  • FIG. 30: FINANCIAL KEDRION BIOPHARMA. BY PRODUCT GROUPS (2013)
  • FIG. 31: SWOT ANALYSIS OF KEDRION BIOPHARMA
  • FIG. 32: CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)
  • FIG. 33: CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
  • FIG. 34: SWOT ANALYSIS OF CSL BEHRING
  • FIG. 35: SWOT ANALYSIS OF BDI PHARMA
  • FIG. 36: FINANCIAL REVENUE OF BAYER HEALTHCARE (2013 AND 2012)
  • FIG. 37: FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2013
  • FIG. 38: SWOT ANALYSIS OF BAYER HEALTHCARE
Back to Top